Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.